The estimated Net Worth of M Anne Szostak is at least $4.63 million dollars as of 6 May 2024. Ms. Szostak owns over 257 units of Idexx Laboratories stock worth over $125,997 and over the last 22 years she sold IDXX stock worth over $4,193,677. In addition, she makes $312,482 as Independent Director at Idexx Laboratories.
M has made over 24 trades of the Idexx Laboratories stock since 2008, according to the Form 4 filled with the SEC. Most recently she sold 500 units of IDXX stock worth $234,685 on 5 September 2024.
The largest trade she's ever made was exercising 11,876 units of Idexx Laboratories stock on 4 February 2021 worth over $888,087. On average, M trades about 887 units every 66 days since 2003. As of 6 May 2024 she still owns at least 257 units of Idexx Laboratories stock.
You can see the complete history of Ms. Szostak stock trades at the bottom of the page.
M. Anne Szostak serves as Independent Director of the Company. Ms. Szostak had a 31-year career with Fleet/Boston Financial Group (now Bank of America), a diversified financial services company, until her retirement in 2004. She served as Chairman and Chief Executive Officer of Fleet Bank-Rhode Island from 2001 to 2003, Chairman, President and Chief Executive Officer of Fleet-Maine from 1991 to 1994, and Corporate Executive Vice President and Chief Human Resources Officer of FleetBoston Financial Group from 1998 to 2004. After her retirement, Ms. Szostak founded Szostak Partners, an executive coaching and human resources consulting firm, and as President of Szostak Partners, she provides strategic advice and counsel to clients. Ms. Szostak holds an undergraduate degree from Colby College, and she has completed several executive education programs at Harvard Business School. Through her executive leadership roles at Fleet/Boston Financial Group, including serving as a chief executive officer of two major bank subsidiaries, Ms. Szostak brings extensive leadership, management, financial services and human resources experience to the Board. In particular, Ms. Szostak has deep expertise in human capital management, which is a key driver for our strategy of innovation. Ms. Szostak also leverages her substantial public company board experience, including in committee chair roles, in her service on our Board, including as Chair of the Compensation Committee.
As the Independent Director of Idexx Laboratories, the total compensation of M Szostak at Idexx Laboratories is $312,482. There are 14 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
M Szostak is 69, she's been the Independent Director of Idexx Laboratories since 2012. There are no older and 25 younger executives at Idexx Laboratories.
M's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers et Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: